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Abstract
Background: Oral isotretinoin (Roaccutane®) revolutionized the treatment of 
acne when it was introduced in 1982. Methods: Twelve dermatologists from 
several countries with a special interest in acne treatment met to formally review 
the survey of their last 100 acne patients treated with oral isotretinoin. The pri­
mary purpose of the survey was to identify the types of acne patients who were 
prescribed oral isotretinoin and how the patients were managed. Results: Of the
1,000 patients reviewed, 55% of those who received oral isotretinoin had those 
indications treated historically, i.e. severe nodular cystic acne or severe inflam­
matory acne, not responding to conventional treatment. Forty-five percent of pa­
tients who were prescribed oral isotretinoin however had either moderate or mild 
acne. Most patients in this group had moderate acne (85%). However, 7.3% had 
mild acne on physical examination. The criteria for prescribing oral isotretinoin 
in this less severe group of patients included acne that improves <50% after 
6 months of conventional oral antibiotic and topical combination therapy, acne 
that scars, acne that induces psychological distress and acne that significantly 
relapses during or quickly after conventional therapy. Treatment is usually 
initiated at daily doses of 0.5 mg/ltg (but may be higher) and is increased 
to 1.0 mg/kg. Most o f the physicians aimed to achieve a cumulative dose of 
>100-120 mg/kg. Mucocutaneous side-effects occur frequently but are manage­
able while severe systemic side-effects are rarely problematic (2%). The terato­
genicity of oral isotretinoin demands responsible consideration by both female 
patients and their physicians. Significant cost savings when treating acne patients 
with oral isotretinoin as compared to other treatment modalities were further 
proven in this study. Conclusions: Our recommendation is that oral isotretinoin 
should be prescribed not only to patients with severe disease but also to patients 
with less severe acne, especially if there is scarring and significant psychological 
stress associated with their disease. Acne patients should, where appropriate, be 
prescribed isotretinoin sooner rather than later.
Introduction
Oral isotretinoin (Roaccutane®) revolutionized the treat­
ment of acne when it was introduced in 1982. More than 
a decade later, it remains the most effective anti-acne
pharmacotherapy since it is the only treatment that affects 
all major aetiological factors implicated in acne. Sebum 
production [1-3], comedogenesis [2], surface and ductal 
colonization with Propionibacterium acnes [1 ,2 ] and mo­
nocyte chemotaxis [2, 4] are all significantly reduced by
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Table 1. Roaccutane usage
Based on the last 100 patients you treated with Roaccutane:
( 1) How were these patients categorized?
Severe acne
Moderate acne ---------
With scarring -------------------
With psychological complications -------------------
With both -------------------
With neither -------------------
Mild acne --------
With scarring -------------------
With psychological complications -------------------
With both -------------------
With neither -------------------
Other, e.g. pyoderma faciale, acne fulminans, gram-negative folliculitis, vasculitic acne
(2) What were your dosage recommendations?
Daily dose, mg/kg -------------------
Therapy duration, weeks -------------------
Total course dose, mg/kg -------------------
Did you vary according to acne severity? -------------------------------------
(3) Do you recommend a total dose (cumulative) to minimize relapse? yes/no
If yes, please continue 
(3a) What cumulative dose do you prescribe?
(3b) In what proportion of patients (percent) do you administer a total cumulative dose?
isotretinoin therapy. Oral isotretinoin is established as a 
uniquely successful therapy capable of long-term remission 
in up to 70-89%  of patients [5-9].
When isotretinoin was first introduced in the early 
1980s, its use was restricted predominantly to patients suf­
fering with severe nodulocystic acne. With increasing clin­
ical experience, however, its use has been expanded by 
many physicians to include patients with less severe disease 
who are responding unsatisfactorily to conventional thera­
pies such as long-term antibiotics and appropriate topical 
therapies. Currently among some physicians, patients with 
nodular acne represent only a small proportion of their iso- 
tretinoin-treated patient population. Thus, if the prescribing 
of isotretinoin is limited by other physicians to patients 
with severe nodular acne, then many patients are not re­
ceiving appropriate therapy and many such patients will 
scar. Unfortunately, more and more patients are failing to 
respond to long-term antibiotics and appropriate topical 
therapies because of an increase in resistance of R acnes 
to many antibiotics, in particular erythromycin and tetracy­
cline [10-13], Even patients with moderate acne can scar 
significantly, and currently there is not much successful 
treatment for the majority of patients who do scar [14-16].
In light of these observations, a review of current 
isotretinoin usage policies and treatment recommendations
was made among dermatologists with a particular interest 
in acne. The ultimate objective was to provide treatment 
guidelines based upon collective clinical experience.
Methods
Based upon evaluation of the last 100 patients treated with oral iso­
tretinoin, each participant completed a questionnaire (cf. table 1) 
which requested detailed information regarding acne indications 
treated, dosage used as well as particular safety and tolerability con­
cerns. Since the safety profile of isotretinoin is predictable consisting 
predominantly of manageable mucocutaneous effects such as cheili­
tis, dry skin and, less frequently, headaches and arthralgias, the ques­
tionnaires focused primarily on indications and dosage.
Since acne classification schemes vary among dermatologists, 
reaching consensus with respect to which types of acne warrant iso­
tretinoin treatment was greatly enhanced by using representative pa­
tient pictures. These pictures covered the whole spectrum of acne 
physical severity. Many patients with mild or moderate acne, let alone 
severe acne, scar, and this feature was captured by the questionnaire. 
The psychological trauma of acne is well documented [17-20] and 
was also covered by the questionnaire. Acne morbidity is determined 
by other influencing factors such as the chronic and/or relapsing na­
ture of the disease and the limited benefit of previous conventional 
therapy.
Isotretinoin has been shown to be cost effective [21-24]. Two cen­
tres re-investigated this issue by comparing the actual total costs of 
isotretinoin therapy with the cost if patients had received other than
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Fig. 1- Percentage of patients treated 
from 7 countries (10 centres: the Italian data 
from 2 centres were combined) with severe 
acne who were treated with oral isotretinoin.
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oral isotretinoin therapy. The patients in the Australian cohort have 
been published elsewhere [22]. The UK data were based on 364 pa­
tients who were followed for 3 years from the start of the first course 
of isotretinoin. Two sets of cost data were calculated as described pre­
viously [21]. The data included all costs, i.e. drug» personnel time and 
overheads. The first set was based on the precise cost for the 364 pa­
tients. It included the initial cost of isotretinoin therapy plus any addi­
tional drug costs incurred for management of side-effects or acne ther­
apy if the acne flared after the initial course of isotretinoin. The second 
set was calculated on a theoretical basis, assuming that isotretinoin 
was not available for these patients. These data assumed that the pa­
tient had requested therapy over this 3-year time period. Our approach 
In the pre-isotretinoin days would have been to prescribe rotational 
antibiotics, i.e. 6 months each of tetracycline, minocycline, trimetho­
prim and erythromycin (plus appropriate topical therapy). To both sets 
of data were added either the real or theoretical costs for all hospital 
overheads.
Results
patients receiving oral isotretinoin had severe acne; in 
Spain, the percentage was 58% and in the two Italian cen­
tres 38%.
Acne Indications
Moderate Acne
All physicians used oral isotretinoin in patients with 
moderate acne that had failed to respond to long-term an­
tibiotics or appropriate topical therapy (fig. 2). In the UK 
and Italy, such patients represented the greatest number of 
patients so treated (UK: 74-76%  and Italy: 50%) whereas 
in Australia, France, Germany and Spain this subpopulation 
represented 16, 18, 20 and 32%, respectively. In the USA, 
21-35% of isotretinoin-treated patients had moderate acne. 
In this subgroup of moderate acne, combined data from 
all countries revealed (fig. 3) that many had either scars 
(16.7%), psychological problems (18.7%) or both (64.2%). 
The percentage of patients with moderate acne who had 
scars and psychological problems was similar in most 
countries.
Severe Acne
As shown in figure 1, all physicians prescribed oral iso-
Mild Acne
All physicians used isotretinoin in patients with mild
tretinoin in all patients with severe acne, but such patients acne which was non-responsive to long-term antibiotics or
represented varying proportions of the isotretinoin-treated appropriate topical therapies. All such patients, however, in
population. Two physicians did not have accurate records this group had either scarring (15.5%) or psychological
of acne severity. Thus, such data from these two centres problems (19%) or both (65.5%). In most countries, this
were not available. In Australia, 82% of the patients who group of ‘mild’ acne represented less than 5% of oral
received oral isotretinoin had severe acne; in France it was isotretinoin usage except one centre, where 12% of all acne
80% and in Germany 70%. In the two USA clinics, the per- patients seen had physically mild acne with either scarring
centage was 60 and 75%. In the UK, only 14-16% of the or psychological distress or both.
Roaccutane Treatment Guidelines Dermatology 1997;194:351-357 353
Fig. 2. Percentage of patients from 7 
countries with m oderate  and mild acne who 
were treated with oral isotretinoin.
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Country
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Acne variants such as acne fulminans, gram-negative 
folliculitis, rosacea fulminans and acne conglobata were 
rare causes for prescribing oral isotretinoin; this reflects 
the very uncommon nature of these diseases* Only 5 such 
patients were reported, ail of whom required oral iso­
tretinoin.
Dosing Regimen , Sicle-Effects and Blood Tests
All physicians used a daily dose of 0.5-1.0 mg/kg and 
adjusted therapy duration to 16-30 weeks, depending upon 
the daily dose. They also adjusted the daily dose according 
to tolerability and all used a cumulative dose per course of 
100 mg/kg or more. In 7 o f the 10 centres, most patients 
reached a cumulative dose of 120 mg/kg.
Mucocutaneous side-effects were experienced by virtual­
ly all patients -  as was to be expected. In only 4% (2-15%) 
were these troublesome and unresponsive to simple mois­
turizers. In such patients, topical steroids were frequently 
prescribed as were antibiotics to manage secondary infec­
tion. The most common systemic side-effects requiring spe­
cific therapy were arthralgias and headaches. Paracetamol 
or non-steroidal anti-inflammatory drugs were all that were 
required. In no patient were the side-effects a major prob­
lem.
Liver function tests and fasting lipids were performed at 
baseline by all authors, but the frequency of repeat blood 
tests varied from centre to centre. Laboratory tests were 
regularly performed by all but two authors. The time and 
frequency of blood tests varied. However, in none of the
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Fig. 3. Percentage of isotretinoin-treated patients with moderate 
acne who had significant scarring and psychological problems or both.
1,000 patients did any of the minor and expected laboratory 
changes (mild elevation of fasting lipids and liver enzymes) 
result in a change of dosage or cessation of therapy.
*
Cost Savings
The cost of treating patients with oral isotretinoin and 
any subsequent therapy with the theoretical cost of long­
term antibiotics had isotretinoin not been available demon­
strated a significant cost saving. This was documented very
<
Scarring Psychological Both
Problems
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Table 2. Mean cost of isotretinoin and any subsequent therapy compared with the theoretical cost if the patient had not been prescribed such 
therapy for 3 years
Severity of acne Percentage 
of patients
Mean cost if treated 
with isotretinoin, GBP
Mean cost without isotretinoin 
treatment, GBP
p value
Mild 20 678 ±45 1,675 ±291 <0.0001
Moderate 57 732±74 1,520± 104.5 <0.0001
Severe 23 803 ±117 1,856±204.5 <0.0001
G B P - Calculated in British pounds. Means ±95% confidence limits.
impressively when treatment costs for acne patients in a in the presence of P. acnes resistance, and it markedly sup- 
country such as the UK were evaluated: comparing the pre- presses the sebum excretion rate by 90% within 1 month of 
cise treatment costs of 364 patients who were prescribed initiating therapy [6, 25]. Thus, it is not surprising that oral 
oral isotretinoin with the theoretical costs of antibiotic isotretinoin is veiy effective in patients with moderate acne 
treatment revealed cost savings of approximately 60% over whatever their reasons for failure. All authors treated some 
conventional 4-month rotational therapy with antibiotics such non-responding patients with isotretinoin. In one clin- 
plus topical agents (table 2). The savings were similar ic, up to 74% of patients treated with oral isotretinoin had 
whether the patient had mild, moderate or severe acne, moderate and non-responsive acne, whereas at the other ex- 
Since most of the patients with mild acne had psychologi- treme it was only 16% so treated. In all clinics, a smaller 
cal problems, an amount for additional counselling and re- percentage of patients with mild acne received oral iso­
assurance was added to the theoretical cost. This explains tretinoin. A high percentage of patients with moderate ac- 
why the theoretical costs of treating mild acne patients are tive acne as so defined had significant scarring and psycho- 
greater than if the patient had moderate acne. logical problems. This was even more evident in those
patients with mild acne who received oral isotretinoin.
Scarring from acne creates enduring physical and emo­
tional ramifications; it should be a compelling rationale for 
isotretinoin treatment, since no other treatment is guaran- 
These data document for the first time worldwide expe- teed to resolve inflammatory acne. Even when conventional 
rience on the overall use of isotretinoin. Isotretinoin should antibiotic therapy is effective, its slower onset of action 
not be limited to patients with severe acne. Acne morbidity may be too late to preclude permanent scarring [15, 16].
Discussion
is determined by more than the apparent physical appear- The significant psychosocial impact of acne should not
ance. Influencing factors include the extent of the disease be underestimated and includes depression, anxiety, inter-
(trunk and extremities may be involved in addition to the personal and work-related difficulties, and attempted suicide
face), the chronic and/or relapsing nature of the disease, the [ 17-20]. Therefore, patients with acne-induced psychologi-
limited benefit of previous conventional therapy, the likeli- cal distress such as severe depression or dysmorphophobia
hood of permanent scarring and the degree of acne-induced should be treated with isotretinoin [15] even when such pa-
psychological trauma.
Patients with severe acne should receive oral isotretinoin
tients display apparently ‘m ild1 acne.
This unnecessary delay of therapeutic response is natu
as first-line therapy Patients responding poorly to conven- rally frustrating for any acne patient seeking medical atten-
tional acne therapy after 6 months are too often prescribed tion but may be permanently detrimental for those who scar
more oral antibiotics before isotretinoin is considered, or who suffer acne-iduced emotional distress [25, 26]. Al-
Many patients fail to respond to antibiotics since propioni- though life quality is impaired in patients with acne as with
bacterial strains resistant to one or more antibiotics are in- many other diseases, few treatments are as effective at
creasingly detected [11-13]. Another reason for poor re- recovering predisease quality of life as is isotretinoin. A
sponse to long-term antibiotics, in the absence of P. acnes recent Oxford study, incorporating four different validated
resistance, is dilution of what could be otherwise effective quality-of-life instruments, confirmed that isotretinoin
therapy by high sebum excretion rates — a characteristic treatment significantly improves social function, mental
feature of acne [2]. Isotretinoin effectively cures acne, even health and self-esteem among other indicators [27].
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Additional indications where isotretinoin is used effec- Table 3. Relationship between the daily dose, the duration of ther- 
tively represent but a small percentage o f patients (<1%) apy and the cumulative dose
and include severe acne variants such as gram-negative fol­
liculitis, inflammatory rosacea (e.g. rhinophyma), acne ful- 
minans. rosacea fulminans and hidradenitis suppurativa.
In this study, the variations in the indication for use of 
oral isotretinoin are, in part, explained by the variation in 
ways medicine is practised in different countries. In the 
UK, all patients with troublesome acne who may require 
oral isotretinoin are treated by a hospital dermatologist, 
simply because the drug is only available from hospitals.
Thus, the physician is more likely to see a broader group of 
patients not responding to conventional therapy. In Europe, 
patients with less severe acne who ought to be prescribed
oral isotretinoin are likely to visit a private practising der- female patient and physician [30-32]. Women of child- 
matologist rather than a hospital dermatologist, whereas the bearing potential must have a negative pregnancy test as 
European hospital/university specialist is more likely to see well as practise effective contraception during and for 1
month after completing therapy [31-33]. Formalized edu-
Daily dose 
mg/kg
Cumulative dose, mg/kg •
4 months 
( 120 days)
5 months 
(150 days)
6 months 
(180 days)
7 months 
(210 days)
0.5 60 75 90 105
0.6 72 90 108 126
0.7 84 105 126 147
0.8 96 120 144 168
0.9 108 135 162 189
1.0 120 150 180 210
the more severe cases o f acne.
Although there were variations in the doses prescribed, cational campaigns by the manufacturer, including preg-
virtually all patients received 0.5-1.0 mg/kg/day, In 4 out of nancy prevention programmes, have been very successful
9 clinics, the dose regimen usually stalled at 0.5 mg/kg [32, 33]. Furthermore, the required 1-month post-therapy
daily and increased to 1.0 mg/kg/day, but in 2 centres most contraceptive period affords a respectable safety margin
patients were started on therapy at 1.0 mg/kg/day. Publish- since it has now been demonstrated that plasma concentra-
ed data indicate that optimal benefit is achieved with the tions of isotretinoin return to physiological levels within 10
higher dose [5, 6, 8, 18, 28, 29]. The term cumulative dose days of therapy completion [34].
per course refers to the total amount o f oral isotretinoin Significant cost savings over traditional acne therapies
taken by the patient over the duration of therapy; in this are well documented for isotretinoin [9, 35-37]. Rotational
study the duration of therapy varied from 16 to 30 weeks, antibiotic therapy is not only less effective than isotretinoin,
Data on cumulative dose indicate that post-therapy relapse slower in onset of action and a potential public health haz-
is minimized by a treatment course amounting to a total of ard in terms of bacterial resistance, but substantially in-
at least 120 mg/kg [6-8, 25, 29] with no further therapeutic creases costs to patients or insurers. Even using an unreal-
gain beyond about 150 mg/kg. istically short treatment period of 2 years for conventional
Most physicians in this study achieved such a cumulative therapy, French costs were estimated to be 15% lower with
treatment dose. Table 3 summarizes the relationship be- isotretinoin [36]. In Australia [22], conventional acne ther-
tween daily dose, duration of therapy and cumulative dose, apy costs for drugs, laboratory tests and physician consulta-
M ucocutaneous side-effects such as dry lips, dry nasal tions are 25% higher than for isotretinoin therapy. Consid-
passages and dry eyes are predictable and dose-dependent ering costs in New Zealand of medicines, laboratory tests
consequences of oral isotretinoin. They were evident in and consultation fees, even the highest dose of isotretinoin
most patients in this series. Pretreatment counselling and (1 mg/kg/day) is 50% less expensive than convential ther-
the regular use of moisturizing agents and lip salves usually apy [37]. Our data confirmed the cost effectiveness of iso-
manage these adverse effects quite effectively. In this se- tretinoin in patients with mild, moderate or severe acne.
lies, 4% of patients had troublesome mucocutaneous side- 
effects.
Professional and governmental health attifudes are fo­
cusing more and more on prevention and cost benefit. We
Severe systemic side-effects are rarely a problem. In this therefore conclude that not only do acne patients gain im-
series, only 2% of patients suffered troublesome effects, in measurable physical and psychological relief with almost
particular headaches, myalgia and arthralgia; all symptoms 100% improvement within 4-6 months of therapy, but soci-
responded to oral paracetamol or non-steroidal anti-inflam- ety gains by limiting bacterial resistance evolution and re-
matory drugs. ducing health care costs. Thus acne patients should, where
W hile oral isotretinoin is effective in treating acne, its appropriate, be prescribed oral isotretinoin sooner rather 
teratogenic risk demands responsible consideration by both than later.
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